Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | BMC Cancer

Fig. 2

From: Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study

Fig. 2

Best response to trabectedin in 71 patients with soft tissue sarcoma. Waterfall plots depict change from baseline in sum of longest diameters of target lesions for each patient according to tumor histology (a) and grade (b). Six patients were excluded from this analysis because CTs were not performed: 3 stopped treatment after cycle 1 for personal reasons, 1 recently started treatment and 2 had early toxicities requiring treatment suspension. Cut-off levels were based on Response Evaluation Criteria in Solid Tumors (RECIST) definitions [23]

Back to article page